The HELIOS Trial Protocol: A Phase III Study of Ibrutinib in Combination with Bendamustine and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia
Future Oncology | June 5, 2014 | Volume: 11 | Issue: 1 | Pages: 51-59
10.2217/fon.14.119
| PMID 24901734